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Abstract
Background: To date, the function of many hypothetical membrane proteins of Mycobacterium tuberculosis is still 
unknown and their involvement in pathogen-host interactions has not been yet clearly defined. In this study, the 
biological activity of peptides derived from the hypothetical membrane protein Rv0679c of M. tuberculosis and their 
involvement in pathogen-host interactions was assessed. Transcription of the Rv0679c gene was studied in 26 
Mycobacterium spp. Strains. Antibodies raised against putative B-cell epitopes of Rv0679c were used in Western blot 
and immunoelectron microscopy assays. Synthetic peptides spanning the entire length of the protein were tested for 
their ability to bind to A549 and U937 cells. High-activity binding peptides (HABPs) identified in Rv0679c were tested 
for their ability to inhibit mycobacterial invasion into cells.
Results: The gene encoding Rv0679c was detected in all strains of the M. tuberculosis complex (MTC), but was only 
transcribed in M. tuberculosis H37Rv, M. tuberculosis H37Ra and M. africanum. Anti-Rv0679c antibodies specifically 
recognized the protein in M. tuberculosis H37Rv sonicate and showed its localization on mycobacterial surface. Four 
HABPs inhibited invasion of M. tuberculosis to target cells by up to 75%.
Conclusions: The results indicate that Rv0679c HABPs and in particular HABP 30979 could be playing an important 
role during M. tuberculosis invasion of host cells, and therefore could be interesting research targets for studies aimed at 
developing strategies to control tuberculosis.
Background
Tuberculosis (TB) is among the top three leading causes
of death by a single infectious agent worldwide. The situ-
ation is further aggravated by the increased susceptibility
of human immunodeficiency virus (HIV)-positive people
to infection with Mycobacterium tuberculosis [1], and by
the emergence of multidrug-resistant (MDR)-TB strains
in many geographical areas [2]. An estimate of nearly 9.2
million cases of TB occurred during 2007, 4.1 million of
which corresponded to new smear-positive cases and
14.8% were reported among HIV-positive people [3].
Unfortunately, the bacillus Calmette-Guérin (BCG)
vaccine is insufficient to control the worldwide spread of
this health threat, especially since it is contraindicated for
HIV-positive people and has a variable efficacy, mostly
due to its low capacity to stimulate the broad cell spec-
trum needed for inducing an effective immune response
[4,5]. Therefore, a large body of research has focused on
searching for new specific antigens of M. tuberculosis that
could be used as new prophylactic alternatives with the
aim of replacing or improving the currently available
BCG vaccine [6-8].
The publication of the complete M. tuberculosis H37Rv
genome sequence has opened a gate for the identification
of genes that encode M. tuberculosis antigens putatively
a b l e  t o  t r i g g e r  a n  e f f e c t i v e  i m m u n e  r e s p o n s e  a n d  t h a t
could therefore be interesting as potential components of
antituberculous subunit vaccines [9,10]. The immunolog-
ical properties of these predicted M. tuberculosis-specific
antigens have been characterized mainly using recombi-
nant proteins [11]. Synthetic peptides have been also used
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with success for screening pathogen-specific genome
regions of putative protective importance in order to
identify T-cell reactivity [12]. In TB, synthetic peptides
have shown good results for diagnosing TB in cattle [13]
and in a protective vaccine tested in mice [14].
The first encounter between M. tuberculosis and the
host cell occurs via an array of different receptor mole-
cules, including complement receptors, the mannose
receptor, the dendritic cell-specific intercellular adhesion
molecule (ICAM)-3-grabbing nonintegrin (DC-SIGN),
and Fc receptors [15]. The recent discovery of novel
classes of receptors such as toll-like receptors, nucle-
otide-binding oligomerization domain (NOD)-like recep-
tors, DC-SIGN, and Dectin-1, are giving clues about the
possible host mechanisms involved in coordinating the
innate and adaptive immune responses against M. tuber-
culosis [16]. Particularly, lipoproteins have been shown to
trigger cytokine signaling via toll-like receptors on the
surface of mammalian cells and therefore have been con-
sidered to be important effectors that may contribute to
the pathogen's virulence. However, only a reduced num-
ber of predicted mycobacteriallipoproteins have been
experimentally characterized [17].
Our institute has studied ligand-receptor interactions
established between synthetic peptides derived from
pathogen proteins and host-cell surface receptors, with
the purpose of identifying high activity binding peptides
(HABPs) involved in specific host-pathogen recognition
interactions, and that could therefore be potential com-
ponents of subunit vaccines. This methodology has been
used and tested on different pathogens, including Plas-
modium falciparum, Plasmodium vivax [18-20], Human
papillomavirus [21] and Epstein-Barr virus [22], among
others. Specifically in the case of M. tuberculosis, our
group has characterized and determined the binding pro-
files of three mycobacterial membrane proteins [23-25].
More recently, the biological relevance of HABPs derived
from some other mycobacterial proteins has been dem-
onstrated using a flow-cytometry-based assay to assess
the capacity of HABPs to mycobacterial inhibit invasion
of target cells [26-28].
This study focused on the Rv0679c protein of M. tuber-
culosis, which is classified as a hypothetical membrane
protein of the cell envelope. Its protein homolog in M.
bovis BCG is a putative lipoprotein that has been shown
to be tightly associated to lipoarabinomannan (LAM)
[29], one of the major components of cell envelope
involved in pro-inflammatory and anti-inflammatory
responses [30]. The aim of the present study was to iden-
tify Rv0679c HABPs capable of inhibiting M. tuberculosis
invasion of target cells that could therefore be considered
as potential as candidate components for a chemically
synthesized, subunit-based antituberculous vaccine.
Methods
Bioinformatics analysis
The sequence of the M. tuberculosis Rv0679c protein was
downloaded from Tuberculist http://genolist.pasteur.fr/
TubercuList/ a nd used as  que ry  seque nc e o f  a  BLAS T
search http://www.ncbi.nlm.nih.gov/BLAST/. Type I and
II signal peptides (typical of lipoproteins) were identified
using LipoP 1.0 http://www.cbs.dtu.dk/services/LipoP/.
Transmembrane regions were predicted using TMHMM
v. 2.0 http://www.cbs.dtu.dk/services/TMHMM and
TMPRED http://www.ch.embnet.org/software/
TMPRED_form.html.
Molecular assays
The presence and transcription of the Rv0679c gene was
assessed in species and strains belonging to the M. tuber-
culosis complex and in mycobacteria other than tubercu-
losis. The following strains were tested (26 in total): M.
tuberculosis  H37Rv (ATCC 27294), M. tuberculosis
H37Ra (ATCC 25177), M. bovis (ATCC 19210), M. bovis
BCG (ATCC 35734), M. africanum (ATCC 25420), M.
microti strain Pasteur (donated by Dr. Françoise Portaels),
M. flavescens (ATCC 14474), M. fortuitum (ATCC 6841),
M. szulgai (ATCC 35799), M. peregrinum (ATCC 14467),
M. phlei (ATCC 11758), M. scrofulaceum (ATCC 19981),
M. avium (ATCC 25291), M. smegmatis (ATCC 14468),
M. nonchromogenicum (ATCC 19530), M. simiae (TMC
1595), M. intracellulare (ATCC 13950), M. gastri (ATCC
15754), M. kansasii (ATCC 12478), M. dierhoferi (ATCC
19340), M. gordonae (ATCC 14470), M. marinum (ATCC
927),  M. terrae (ATCC 15755), M. chelonae-chelonae
(ATCC 35752), M. vaccae (ATCC 15483), M. triviale
(ATCC 23292). All mycobacterial strains were cultured
for 5 to 15 days in Middlebrook 7H9 medium (Difco, New
Jersey, USA) containing 0.05% Tween 80. Growth media
were supplemented with oleic acid-albumin-dextrose-
catalase (OADC) (Becton Dickinson, BBL; Sparks, MD)
or ADC as needed. Genomic DNA isolated phenol-chlo-
roform extraction, as described elsewhere [31]. PCR
assays were carried out on a GeneAmp PCR System 9600
thermal cycler (Perkin-Elmer Life Sciences Inc., Boston,
MA,  U S A )  u s i n g  0 . 4  m M  o f  d i r ec t  ( 5 ' - C GCT A C C CA -
CTCCCG-3') and reverse primers (5'-CTTGTTGTTCG-
CACCAC-3') to amplify a 346-bp fragment of Rv0679c.
Thermocycling conditions consisted of an initial denatur-
ation at 94°C for 5 min, followed by 25 cycles according to
the following conditions: 56°C for 30 s, 72°C for 40 s and
95°C for 40 s. A final 5 min extension step was performed
at 72°C. Amplification products were separated in SYBR-
stained 1% (w/v) agarose gels (Invitrogen).
For RT-PCR assays, RNA was isolated based on
Katoch's methodology [32], assessing transcription of the
rpoB housekeeping gene as positive transcription control
[33].Cifuentes et al. BMC Microbiology 2010, 10:109
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Detection of Rv0679c by Western blot and immunoelectron 
microscopy (IEM)
Expression of the Rv0679c gene was assessed by Western
blot analysis of M. tuberculosis H37Rv sonicates using
sera raised in goats obtained. Briefly, two goats (A-29 and
B-86) nonreactive to M. tuberculosis H37Rv sonicate
were inoculated with 5 mg of either polymerized forms of
peptide 28528
(43CGTTTPATATTTTATSGPTAAPGC62) or peptide
28530 (145CGTYKNGDPTIDNLGAGNRINKEGC165),
both in polymeric form and emulsified with Freund's
incomplete adjuvant. These two peptides were chosen
because the BepiPred 1.0b server http://www.cbs.dtu.dk/
services/BepiPred/ predicted them as B cell epitopes.
Subcellular localization was determined in a CM 10
transmission electron microscope (Philips, Suresne,
Hauts-de-Seine, France), using thin slices (400 nm) of LR-
White resin embedded mycobacteria. Goat anti-peptide
sera were used as primary antibody and anti-goat IgG
coupled to 10-nm colloidal gold particles as secondary
antibody. Slices were stained with 6% uranyl acetate to
enhance image contrast.
Interaction of Rv0679c peptides with target cells
Nine nonoverlapping 20-mer-long peptides spanning the
entire length of Rv0679c were synthesized and 125I-
labeled according to previously described techniques [34-
36]. Peptides were tested for their ability to bind to the
A549 alveolar cell line (ATCC CLL-185) and to mac-
rophages derived from U937 monocytes (ATCC CRL-
2367). Briefly, 1.5 × 106 cells cultured in Roux flasks were
dislodged using 1× Non-enzymatic Cell Dissociation
Solution (Sigma) and incubated with increasing concen-
trations of 125I-labeled peptide (0-950 nM) in the pres-
ence or absence of unlabeled peptide (40 μM). Unbound
peptide was removed using a dioctylphthalate-dibu-
tylphthalate cushion, before measuring cell-associated
radioactivity in a gamma counter (Gamma Counter
Cobra II, Packard Instrument Co., Meriden, CT, USA).
Total binding minus nonspecific binding yielded the
specific binding curve, whose slope corresponded to the
binding activity of the peptide. Any peptide displaying a
specific binding activity of ≥1% was considered a HABP
[23-25,37]. Binding constants were determined by per-
forming a saturation assay using U937 cells and peptide
concentrations larger than the ones used for binding
assays (0-4500 nM).
Circular dichroism analyses of Rv0679c peptides
The secondary structure elements of the peptides span-
ning the entire length of Rv0679c were studied by circular
dichroism. CD spectra of peptides (5 μM) dissolved in
30% trifluoroethanol (TFE) were acquired at 20°C by
averaging three scans taken in a Jasco J-810 spectropola-
rimeter (wavelength range: 260-190 nm, scan rate: 20
nm/min, bandwidth: 1 nm), using a 1.00-cm pathway
cuvette (Jasco Inc, Easton, MD). Data were corrected for
baseline deviation [38]. The results were expressed as
mean residue ellipticity [θ], the units being degrees × cm2
× dmol-1 according to the [Θ] = Θλ/(100lcn) function,
where θλ is the measured ellipticity, l is the optical path
length, c is the peptide concentration, and n is the num-
ber of residues in the amino acid sequence.
Invasion inhibition assays
Rv0679c HABPs were assessed for their ability to inhibit
mycobacterial invasion using a flow-cytometry-based
assay developed by Bermúdez and Goodman [39] and
later modified by us [26]. In brief, A549 and U937 cells (1
× 106) seeded overnight on 6-well plates were incubated
for 1 h with different peptide concentrations. SYBR-safe
stained mycobacteria (10 × 106) suspended in RPMI
medium were added to each well (MOI: 1:10) and incu-
bated overnight at 37°C. Inhibition controls consisted of
Cytochalasin D (3 μM) or colchicine (50 μM). Extracellu-
lar bacilli were first inactivated by incubation with Ami-
kacin (200 μg/mL) for 1 h and then removed by
successive washes with Hanks Balanced Salt Solution
(HBSS). Cells were dislodged from monolayers and
stained with methylene blue for FACscan flow cytometry
analysis (Becton Dickinson). The percentage of SYBR safe
positive events in the flanked region were determined by
registering a total of 30 000 events (only infected cells
were detected on the FL1 channel due to their fluores-
cence characteristics). Data were statistically analyzed by
applying a student's t-test.
Internalization of latex beads
Internalization assays were carried out according to a
methodology reported by El-Shazly and colleagues [40].
Briefly, A549 cells (1 × 106) were exposed to peptide-
coated fluorescent beads for 3 h. After removing nonin-
ternalized beads by washing cell thrice with HBSS, cells
were dislodged from the monolayer and analyzed in a
FACscan flow cytometer, same as described in invasion
inhibition assays. The same assay was carried out using
uncoated beads as negative control. An additional assay
was carried out to determine whether the peptide alone
enabled internalization of the latex beads by modifying
the host cell membrane or whether internalization
depended on the interaction between the peptide and the
bead. For this assay, the control consisted on incubating
cells for 2 h only with the peptide and then for 1 h with
uncoated beads.
Results
Molecular analysis of the Rv0679c gene
Two primers flanking the region encoding amino acids
10-125 of Rv0679c were designed and synthesized in
order to determine whether the gene was present inCifuentes et al. BMC Microbiology 2010, 10:109
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strains of the M. tuberculosis complex (MTC). An ampli-
fication band of a 346-bp band was detected in M. tuber-
culosis H37Rv, M. tuberculosis H37Ra, M. bovis, M. bovis
BCG, M. africanum and M. microti (Figure 1A, lanes 2-7,
respectively), but not in the remaining Mycobacterium
strains analyzed in this study. Similarly, cDNA reverse
transcription with the same primers confirmed transcrip-
tion of the gene in M. tuberculosis H37Rv, M. tuberculosis
H37Ra and M. africanum, as indicated by the amplifica-
tion of a single 346-bp band (Figure 1B, lanes 2, 3 and 7,
respectively). No amplification was detected in M. bovis,
M. bovis BCG and M. microti, therefore suggesting that
the gene is not transcribed in these species despite being
present in these species. Amplification of the 360-bp
fragment corresponding to the housekeeping gene rpoB
was evidenced in all strains (Figure 1C).
Goat anti-Rv0679c antibodies specifically recognized 
bands of about 18 and 20 kDa on M. tuberculosis sonicate 
and localized the protein on the surface
Recognition of native Rv0679c protein in M. tuberculosis
s o n i c a t e  b y  a n t i b o d i e s  r a i s e d  i n  g o a t  a g a i n s t  t h e  t w o
polymerized synthetic peptides of Rv0679c was assessed
by Western blot (Figure 2). Serum raised against polym-
erized peptide 28530 in the B-86 goat recognized two
bands in M. tuberculosis sonicate with apparent molecu-
lar weights of 18 and 20 kDa (Figure 2, lane 3), of which
the molecular mass of the first band is more in agreement
with the molecular mass predicted for Rv0679c based on
nucleotide sequence (16.6 kDa). According to IEM stud-
ies performed using the same serum, Rv0679c is most
likely located on mycobacterial surface since the vast
majority of gold particles were detected on the bacilli sur-
face (see black arrows in Figure 3), whereas no immuno-
labeling was observed when the pre-immune serum was
used (data not shown).
Binding of Rv0679c peptides to U937 and A549 cells
A highly specific binding assay was used to evaluate
ligand-receptor interactions established between
Rv0679c peptides and A549 and U937 cell surface recep-
tors, same as has been reported for other mycobacterial
proteins [23-25,37]. Based on this methodology, two
HABPs binding with high activity to both cell lines were
identified (namely HABPs 30979 and 30987), while other
two HABPs (30985 and 30986) bound only to A549 cells.
Figure 4a shows the sequences of Rv0679c synthetic pep-
tides with their corresponding binding activities to A549
and U937 cells. All HABPs identified in Rv0679c were
located toward the protein's C-terminus, except for
HABP 30979 which was localized in the N-terminal end.
Rv0679c HABPs 30979 and 30987 were assessed by
means of a saturation assay using concentrations of radio-
labeled peptide larger than the ones used in conventional
binding assays in order to determine dissociation con-
stants (Kd), Hill coefficients (nH) and approximate num-
ber of binding sites per cell (Figure 4b). The results
showed that binding of these HABPs to surface receptors
of U937 cells was saturable and of cooperative nature (nH
= 1.50 for HABP 30979 and nH = 1.12 for HABP 30987). A
dissociation constant of 1,100 nM and about 1.0 × 106
binding sites per cell were identified for HABP 30979,
while HABP 30987 showed a dissociation constant of 600
nM and about 1.8 × 106 binding sites per cell.
Secondary structure analyses of Rv0679c peptides by 
circular dichroism
CD spectra of Rv0679c peptides obtained in 30% TFE are
shown in Figure 5. The spectra of peptides 30982 and
30987 showed random coil structures, while the spectra
of peptides 30979, 30981 and 30985 were consistent with
α-helical structures. The remaining peptides of Rv0679c
(30980, 30983, 30984 and 30986) displayed θλ values not
related to any defined structures.
Inhibition of M. tuberculosis H37Rv invasion into A549 and 
U937 cells
The ability of Rv0679c HABPs to block mycobacterial
entrance into A549 and U937 cells was evaluated using a
flow-cytometry-based assay. Rv0679c peptides analyzed
in such assay included peptides 30979 and 30987, which
had been identified as HABPs for both cell lines, peptides
30985 and 30986 which had been identified as HABPs for
A549 cells, and a low activity binding peptide (30982)
w h i c h  w a s  u s e d  a s  n e g a t i v e  c o n t r o l .  I n v a s i o n  o f  U 9 3 7
cells was significantly inhibited by HABPs 30985 and
30986, but neither of these two HABPs showed a clear
dose-dependent inhibitory behavior. Peptides 30985 and
30986 showed some signs of cytotoxicity when they were
used at the largest peptide concentration (200 μM), as
indicated by the lost of a portion of the cell monolayer
and an abrupt decrease in percentages of invasion inhibi-
tion. No other peptide showed cytotoxic effects.
HABPs 30985 to 30987 inhibited invasion of A549 cells
by 20%, while HABP 30979 inhibited invasion of both cell
lines in a dose-dependent manner. Moreover, the latter
HABP inhibited invasion of U937 cells by a significantly
larger percentage than the inhibition controls, whereas its
inhibition ability in A549 cells was similar to the one
shown by the controls. These results suggest that
Rv0679c HABPs can prevent invasion of cells targeted by
M. tuberculosis H37Rv. On the other hand, HABP 30987
inhibited invasion to U937 cells by a lower percentage
compared to controls, but showed the highest inhibition
percentage at the lowest peptide concentration used in
this assay (Figure 6a). The negative control peptide did
not inhibit cell invasion by mycobacteria (data not
shown).Cifuentes et al. BMC Microbiology 2010, 10:109
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Figure 1 Molecular assays. (A) 346-bp PCR product was only amplified from genomic DNA of species and strains belonging to the M. tuberculosis 
complex (MTC). (Lane 1) Molecular weight marker (MWM). (Lane 2) M. tuberculosis H37Rv. (Lane 3) M. tuberculosis H37Ra (ATCC 25177). (Lane 4) M. bovis. 
(Lane 5) M. bovis BCG. (Lane 6) M. africanum. (Lane 7) M. microti strain Pasteur. (Lane 8) M. flavescens. (Lane 9). M. fortuitum. (Lane 10) M. szulgai. (Lane 11) 
M. peregrinum. (Lane 12) M. phlei. (Lane 13) M. scrofulaceum. (Lane 14) M. avium. (Lane 15) M. smegmatis. (Lane 16) MWM. (Lane 17) M. nonchromogenicum. 
(Lane 18) M. simiae. (Lane 19) M. intracellulare. (Lane 20) M. gastri. (Lane 21)M. kansasii. (Lane 22) M. dierhoferi. (Lane 23) M. gordonae. (Lane 24), M. marinum. 
(Lane 25) M. terrae. (Lane 26) M. chelonae-. (Lane 27) M. vaccae. (Lane 28) M. triviale. (Lane 29) PCR negative control. (B) Detection of Rv0679c transcription 
in the MTC by RT-PCR using primers specific for the 346-bp fragment. (Lanes 1-7) same as in panel A. (Lane 8) M. tuberculosis DNA treated with DNAse 
Q (Negative control). (Lane 9) PCR positive control (M. tuberculosis H37Rv DNA). (Lane 10) PCR negative control. (C) RT-PCR detection of rpoB transcript 
as positive transcription control in the same strains.Cifuentes et al. BMC Microbiology 2010, 10:109
http://www.biomedcentral.com/1471-2180/10/109
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Rv0679c HABPs 30986 and 30979 facilitate internalization 
of latex beads
A possible role for Rv0679c HABPs in host cell invasion
was evaluated by determining their ability to facilitate
internalization of fluorescent latex beads by A549 cells
when beads are coated with these HABPs. Rv0679c pep-
tides tested in this assay included 30979, 30985-30987,
and peptide 30982 which was used as negative control. As
it can be observed in Figure 6b, the highest internaliza-
tion percentage was achieved when latex beads were
coated with HABP 30979, followed by peptides 30985
and 30987. The percentage of internalization decreased
when latex beads were coated with HABP 30986 com-
pared to internalization of latex beads coated with the
control peptide 30982. However, when cells were incu-
bated first with each HABP and then with uncoated latex
beads (control), smaller internalization percentages were
found for all HABPs, and such percentages were smaller
than the ones found when cells were incubated only with
the beads (no peptide).
Discussion
The mycobacterial cell envelope is a lipid-rich complex
structure that surrounds the bacillus and is thought to
play a critical role in the pathogenicity of Mycobacterium
tuberculosis. Nearly 2.5% of the M. tuberculosis H37Rv
proteome is predicted to consist of lipoproteins [17]. A
large number of these mycobacterial lipoproteins have
been suggested to be important components for the syn-
thesis of the mycobacterial cell envelope, as well as for
sensing processes, protection from stressful factors and
host-pathogen interactions; nevertheless, the function
and localization of a considerable number of putative
lipoproteins remains yet unknown [41].
Lipoproteins are translocated across the cytoplasmic
membrane and then anchored to either the periplasm or
the outer membrane and have been suggested to play
important roles related to virulence because they are pre-
dicted to participate in intracellular transport, cell-wall
metabolism, cell adhesion, signaling and protein degrada-
tion [42]. Rv0679c was initially classified as a hypothetical
membrane protein of M. tuberculosis [9] and was later
suggested to be a putative lipoprotein [29]. It is a 165-
Figure 2 Western blot analysis of M. tuberculosis H37Rv sonicate 
with goat B-86's serum raised against the polymerized Rv0679c 
peptide (CGTYKNGDPTIDNLGAGNRINKEGC). (Lane 1) Molecular 
weight marker (MWM). (Lane 2) Pre-immune serum. (Lane 3) Final 
bleeding serum. The image shows strong recognition of a 20-kDa 
band and a slighter recognition of an 18-kDa band by the final bleed-
ing serum.
Figure 3 Subcellular localization of the Rv0679c protein in M. tu-
berculosis H37Rv bacilli as assessed by IEM. The arrows indicate the 
position of Rv0679c on mycobacterial surface. In this experiment, a 
1:20 dilution of B-86 goat's serum was used as primary antibody and a 
1:50 dilution of 10-nm gold-labeled anti-goat IgG as a secondary anti-
body.Cifuentes et al. BMC Microbiology 2010, 10:109
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amino-acid-long protein with a theoretical molecular
mass of 16.6 kDa, whose function has not been fully char-
acterized yet.
In this study, PCR and RT-PCR techniques were used to
examine the distribution of the Rv0679c gene in the
MTC, as well as in mycobacteria other than tuberculosis
(which included saprophytic and environmental species),
with the aim of establishing a preliminary relationship
between the presence of the protein encoding gene in a
particular mycobacterial species and its virulence, con-
sidering that to develop a subunit antituberculous vac-
cine, it would be better to select peptides (more
specifically HABPs) from M. tuberculosis proteins
involved in host cell invasion that are exclusively present
in MTC or in mycobacterium species related to invasive
processes or causing disease, such as Rv0679c. The
results of this study indicate that the gene encoding
Rv0679c is present in the MTC, as shown by the PCR
amplification of a 346-bp band from genomic DNA of M.
tuberculosis  H37Rv,  M. tuberculosis H37Ra,  M. africa-
num, M. bovis, M. bovis BCG and M. microti; but no
amplification was detected in Mycobacterium spp. strains
outside the complex. Nevertheless, it is worth noting that
Rv0679c homologues have been recently reported in dif-
ferent  Mycobacterium  genomes (e.g. M. smegmatis, M.
marinum and M. avium), which indicates that such prim-
ers are specific for the MTC strains assessed in this study.
Furthermore, reverse transcription assays indicate that
the gene is actively transcribed in M. tuberculosis H37Rv,
M. tuberculosis H37Ra and M. africanum. Intriguingly,
Figure 4 Interaction of Rv0679c peptides with target cells. (A) Binding profiles of peptides derived from Rv0679c to A549 and U937 cells. The 
slope of the specific binding curve is represented by the length of the black horizontal bars shown in front of each peptide sequence. Peptides show-
ing a slope ≥1% were considered to be HABPs. Numbers shown in the first column correspond to our institute's serial numbering system. Superscripts 
at the beginning and end of the sequence indicate the peptide amino acid position within the protein. (B) Saturation binding curves for HABPs 30979 
and 30987 binding with high activity to U937 cells. Saturation curves were obtained by plotting the specifically bound 125I-HABP concentration versus 
free 125I-HABP. Affinity constants and the maximum number of binding sites per cell were obtained from these curves. Inset: the abscissa is log F in 
the Hill plot and the ordinate is log [B/(Bm - B)], where Bm is the maximum amount of bound peptide, B is the amount of bound peptide and F is the 
amount of free peptide.Cifuentes et al. BMC Microbiology 2010, 10:109
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although expression of Rv0679c homologous protein in
M. bovis BCG was described by Matsuba et al. [29], gene
transcription was not detected in M. bovis nor in M. bovis
BCG in this study under normal culture conditions.
Once the presence and transcription of Rv0679c was
determined in the MTC, the next step consisted in evalu-
ating protein expression by Western blot analysis of M.
tuberculosis H37Rv sonicate. Goat anti-Rv0679c peptide
serum detected two bands of about 18 and 20 kDa, which
differ from the theoretical molecular mass of 16.6 kDa
predicted based on its amino acid composition. This
slight difference could be caused by the post-translational
modifications that lipoproteins undergo before reaching
their destination as mature proteins, considering that
pro-lipoproteins tend to be 2-3 kDa larger than mature
lipoproteins [41].
According to bioinformatics predictions, Rv0679c lacks
of transmembrane regions and contains an N-terminal
signal sequence as well as a SPAse II cleavage site
between residues 32-33, as indicated by the presence of a
"lipobox" motif [LAGC] between amino acids 30-33. The
presence of a signal peptide detected by using SignalP
suggests that this protein is secreted via the Sec-depen-
d e n t  p a t h w a y ,  a n d  i s  p r o b a b l y  t a r g e t ed  b y  t h e  l i po bo x
motif to membrane surface where it remains attached by
hydrophobic interactions. Briefly, after Rv0679c is trans-
located across the cytoplasmic membrane, the Cys resi-
due of the lipobox motif is linked to a diacylglyceryl
moiety. Then, a signal II peptidase cleaves off the signal
peptide and the protein is anchored to the mycobacterial
membrane via the diacylglyceryl moiety [41]. These com-
putational predictions are in agreement with the cellular
localization observed in IEM studies in which the protein
was detected on the surface of M. tuberculosis H37Rv
bacilli.
To determine whether the peptides comprising
Rv0679c established ligand-receptor interactions with M.
tuberculosis susceptible human host cells, binding assays
were performed with the U937 phagocytic and A549 epi-
thelial cell lines. HABPs 30985 to 30987 comprising
amino acids 121-165 showed higher binding activities to
receptors on the surface of epithelial cells, whereas their
binding activities to the phagocytic line were lower. Such
differential binding behavior may be caused by differ-
ences between the surface receptors expressed by each
cell line or their distinct physiological functions.
Interestingly, Rv0679c HABPs 30985, 30986 and 30987
are consecutively positioned within the protein's C-ter-
minus, suggesting that the region formed by these three
HABPs is implicated in binding of M. tuberculosis to tar-
get cells. Also, the Hill analysis showed high binding
affinity interactions with a large number of receptor mol-
ecules on the surface of U937 cells, as indicated by their
dissociation constant within the nanomolar range. More-
over, the formation of ligand-receptor complexes appears
to facilitate binding of more HABPs, as shown by the pos-
itive Hill coefficient.
All HABPs tested in invasion inhibition assays pre-
vented cell invasion by M. tuberculosis by a larger or com-
parable percentage, compared to the colchicine and
Cytochalasin D controls. Regarding HABP 30986, an
inhibitory effect similar to the one shown by HABPs
30985 and 30987 was observed on A549 cells at all con-
centrations used in this assay. Moreover, HABP 30987
showed larger inhibitory effect at the smaller concentra-
tion tested in this assay. HABP 30979 inhibited invasion
of both cell types by a larger or even higher percentage
than the ones shown by the colchicine and Cytochalasin
controls. This HABP showed a dose-dependent inhibi-
tory effect on both cells, achieving the highest inhibitory
percentage at 200 μM.
The ability of Rv0679c peptides to inhibit M. tuberculo-
sis invasion of target cells suggests that active and specific
binding to cell surface receptors prevents entry of M.
tuberculosis through this invasion pathway. Such notion
is further supported by the results of internalization
Figure 5 CD spectra of Rv0679c peptides. HABPS spectra were 
grouped in order to enable scale appreciation. Spectra were obtained 
by averaging three scans taken at 0.1 nm intervals from 260-190 nm at 
20°C. [Θ] is the mean residue ellipticity per amino acid residue in the 
peptide. CD resolution: 0.1 millidegree (at ± 2.000 mdeg).Cifuentes et al. BMC Microbiology 2010, 10:109
http://www.biomedcentral.com/1471-2180/10/109
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Figure 6 Invasion inhibition and latex beads internalization assays. (A) Results of invasion inhibition asssays performed with A549 and U937 cells 
and increasing concentrations of Rv0679c HABPs. (B) Internalization of peptide-coated beads by A549 epithelial cells. Dark gray columns correspond 
to the percentage of internalized peptide beads. Peptide 30982 was used as control. White columns correspond to the percentage of uncoated beads 
internalized when the assay was carried out incubating cells first with the peptide and then with uncoated latex beads. Striped columns correspond 
to the percentage of internalized beads when cells were incubated only with uncoated beads. Inset: latex beads internalized by A549 cells observed 
with fluorescence microscopy. The results correspond to the average invasion percentage calculated for each treatment ± standard deviations. *p ≤ 
0.05; **p ≤ 0.01, according to a two-tailed student t-test.Cifuentes et al. BMC Microbiology 2010, 10:109
http://www.biomedcentral.com/1471-2180/10/109
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assays carried out with peptide-coated latex beads and
epithelial cells, where peptide-coated beads were more
actively internalized than uncoated beads. Particularly
HABP 30979, which was the strongest invasion inhibitor,
displayed the highest internalization percentages.
On the other hand, the large inhibition percentages
obtained with phagocytic cells in comparison to the ones
obtained with epithelial cells might be explained by the
cooperativity phenomenon observed in saturation assays
with the phagocytic cell line, since the amount of peptide
that binds to surface receptors is proportional to the
probability of forming more stable ligand-receptor com-
plexes and thereby of restricting mycobacterial entrance.
Furthermore, since some HABPs showed high binding
activity to one cell type but low binding activity to the
other one, it could be suggested that peptide binding
activity depends on specific receptor molecules
expressed on each cell type. Consequently, binding of
Rv0679c HABPs with high activity to both cell lines could
be due to the presence of the same receptor on both cell
types or to different receptors with similar characteris-
tics.
To date, no structural model has been reported for this
protein. Therefore, CD assays were conducted in order to
determine whether there was a relationship between the
secondary structure of Rv0679c peptides and their bind-
ing ability or in their ability to inhibit mycobacterial inva-
sion. CD spectrum data suggested that the secondary
structure of HABP 30979 and 30985 was formed by α-
helix and random coil elements, while peptides 30982 to
30984 and HABPs 30986 and 30987 showed undefined
structural features. The results indicate that there is not a
direct relationship between the structure of HABPs and
their ability to binding to target cells.
Interestingly, the results obtained in this study showed
that the HABPs that inhibited mycobacterial invasion to
target cells more efficiently were also the ones that
showed the larger internalization percentages, therefore
suggesting that Rv0679c HABPs promote entry of patho-
genic  M. tuberculosis into host cells. Specifically, the
binding region formed by HABPs 30985-30987 at the
protein's C-terminal region appears to have a key role
during M. tuberculosis invasion.
The confirmation of Rv0679c's location in mycobacte-
rial surface, together with the identification of a binding
region formed by HABPs 30985-30987, suggest that this
protein may be related to adhesion and/or invasion pro-
cesses. In addition, such surface localization could be
facilitating contact between the bacilli and its host cell,
thereby leading to triggering the host's immune response
via interaction with host cell surface receptors [16].
Conclusions
The complexity of Mycobacterium tuberculosis as a
pathogen and the variety of mechanisms that it uses for
invading host cells makes it necessary to develop an effec-
tive strategy to block the invasion of target cells. Our pro-
posal is based on searching for fragments of different
proteins involved in the mycobacteria-host cell interac-
tion. In our experience, sequences that bind specifically
to target cells and that are capable of blocking invasion
could be used as template to design peptides with ability
to immunomodulate the protective response against
tuberculosis. The immune response triggered against
mycobacterial high-specific binding sequences could pre-
vent invasion of target cells, either during a first encoun-
ter with the bacillum or during the reactivation of a latent
infection.
I t  h a s  b e e n  r e p o r t e d  t h a t  a  c o n s i d e r a b l e  n u m b e r  o f
secreted proteins are protective antigens and therefore
have been considered as attractive candidates to develop
subunit vaccines [43-46]. Moreover, they are hypothe-
sized to mediate mycobacterial entry into the host cell
[47].
Traditionally, vaccine development has been founded
on the humoral immune response, which involves anti-
body production and is mainly targeted against extracel-
lular microorganisms, whereas the immune response
against intracellular microorganisms is mainly driven by
cellular immune mechanisms. In addition, the distinction
between the Th1 and Th2 cellular immune responses is
complex for some of the antigens or immunogens
included in vaccines that induce cellular as well as
humoral immune responses, and it is not yet clear the
degree of independence between antibody-mediated and
cell-mediated immune responses under physiological
conditions [48,49].
Considering the variety of broad interactions of B lym-
phocytes with cellular immunity, B cells could have a sig-
nificant impact on the outcome of airborne challenge
with M. tuberculosis as well as the resultant inflammatory
response [49]. Therefore, we expect for peptides of
Rv0679c to induce an immune response where humoral
and cellular immunity are not mutually excluded.
The identification of Rv0679c HABPs capable of inhib-
iting target cell invasion by M. tuberculosis via host-cell
receptor interactions supports their inclusion in further
immunological studies in animal models aimed at evalu-
ating their potential as components of a subunit-based
antituberculous vaccine.
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